PlumX Metrics
Embed PlumX Metrics

Continuous irrigation with thrombolytics for intraventricular hemorrhage: case–control study

Neurosurgical Review, ISSN: 1437-2320, Vol: 47, Issue: 1, Page: 40
2024
  • 1
    Citations
  • 0
    Usage
  • 2
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Researchers from University of New Mexico Report Recent Findings in Cardiovascular Research (Continuous Irrigation With Thrombolytics for Intraventricular Hemorrhage: Case-control Study)

2024 FEB 09 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Hematology Daily -- Data detailed on Cardiovascular Research have been presented. According

Article Description

Intraventricular hemorrhage (IVH) is a complication of a spontaneous intracerebral hemorrhage. Standard treatment is with external ventricular drain (EVD). Intraventricular thrombolysis may improve mortality but does not improve functional outcomes. We present our initial experience with a novel irrigating EVD (IRRAflow) that automates continuous irrigation with thrombolysis. Single-center case–control study including patients with IVH treated with EVD compared to IRRAflow. We compared standard demographics, treatment, and outcome parameters between groups. We developed a brain phantom injected with a human clot and assessed clot clearance using EVD/IRRAflow approaches with CT imaging. Twenty-one patients were treated with standard EVD and 9 patients with IRRAflow. Demographics were similar between groups. Thirty-three percent of patients with EVD also had at least one dose of t-PA and 89% of patients with IRRAflow received irrigation with t-PA (p = 0.01). Mean drain days were 8.8 for EVD versus 4.1 for IRRAflow (p = 0.02). Days-to-clearance of ventricular outflow was 5.8 for EVD versus 2.5 for IRRAflow (p = 0.02). Overall clearance was not different. Thirty-seven percent of EVD patients achieved good outcome (mRS ≥ 3) at 90 days versus 86% of IRRAflow patients (p = 0.03). Assessing only t-PA, reduction in mean days-to-clearance (p = 0.0004) and ICU days (p = 0.04) was observed. In the benchtop model, the clot treated with IRRAflow and t-PA showed a significant reduction of volume compared to control. Irrigation with IRRAflow and t-PA is feasible and safe for patients with IVH. Improving clot clearance with IRRAflow may result in improved clinical outcomes and should be incorporated into randomized trials.

Bibliographic Details

Carrera, Diego A; Mabray, Marc C; Torbey, Michel T; Andrada, Jason E; Nelson, Danika E; Sarangarm, Preeyaporn; Spader, Heather; Cole, Chad D; Carlson, Andrew P

Springer Science and Business Media LLC

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know